

# SAFETY DATA SHEET



## Serum Gonadotrophin Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5445456-00010      Date of last issue: 04.12.2024  
Date of first issue: 20.02.2020

---

### Section 1: Identification

Product name : Serum Gonadotrophin Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908  
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON)    0800 243 622 (0800  
CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

### Section 2: Hazard identification

#### GHS Classification

Reproductive toxicity : Category 1

#### GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360Fd May damage fertility. Suspected of damaging the un-born child.

Precautionary statements :

#### Prevention:

P201 Obtain special instructions before use.

P280 Wear protective gloves/ protective clothing/ eye protec-tion/ face protection.

#### Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

# SAFETY DATA SHEET



## Serum Gonadotrophin Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5445456-00010      Date of last issue: 04.12.2024  
Date of first issue: 20.02.2020

---

### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

---

### Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Gonadotropin, pregnant mare serum	9002-70-4	>= 30 -< 50

---

### Section 4: First-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.  
May damage fertility. Suspected of damaging the unborn child.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

---

### Section 5: Fire-fighting measures

**Serum Gonadotrophin Formulation**

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5445456-00010      Date of last issue: 04.12.2024  
Date of first issue: 20.02.2020

---

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Metal oxides Oxides of phosphorus
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

**Section 6: Accidental release measures**

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding

**Serum Gonadotrophin Formulation**

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5445456-00010      Date of last issue: 04.12.2024  
Date of first issue: 20.02.2020

---

certain local or national requirements.

**Section 7: Handling and storage**

Technical measures	: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
Conditions for safe storage	: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents

**Section 8: Exposure controls/personal protection****Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Gonadotropin, pregnant mare serum	9002-70-4	TWA	4 µg/m3 (OEB 4)	Internal
		Wipe limit	40 µg/100 cm <sup>2</sup>	Internal

# SAFETY DATA SHEET



## Serum Gonadotrophin Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5445456-00010      Date of last issue: 04.12.2024  
Date of first issue: 20.02.2020

---

### Engineering measures

: The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially contaminated clothing.

---

### Section 9: Physical and chemical properties

Appearance : powder

# SAFETY DATA SHEET



## Serum Gonadotrophin Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5445456-00010      Date of last issue: 04.12.2024  
Date of first issue: 20.02.2020

---

Colour	: white
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: Not applicable
Evaporation rate	: Not applicable
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: Not applicable
Relative vapour density	: Not applicable
Relative density	: No data available
Density	: No data available
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: Not applicable
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.

# SAFETY DATA SHEET



## Serum Gonadotrophin Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5445456-00010      Date of last issue: 04.12.2024  
Date of first issue: 20.02.2020

---

Molecular weight : No data available

Particle characteristics

Particle size : No data available

---

### Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

### Section 11: Toxicological information

Exposure routes : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### **Gonadotropin, pregnant mare serum:**

Acute oral toxicity : LD50 (Mouse): 120 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Mouse): > 1,700 mg/kg  
Application Route: Intravenous

LD50 (Mouse): > 1,700 mg/kg  
Application Route: Subcutaneous

LD50 (Rat): 500 mg/kg  
Application Route: Intravenous

LD50 (Rat): 500 mg/kg  
Application Route: Subcutaneous

# SAFETY DATA SHEET



## Serum Gonadotrophin Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5445456-00010      Date of last issue: 04.12.2024  
Date of first issue: 20.02.2020

---

### **Skin corrosion/irritation**

Not classified based on available information.

#### **Components:**

##### **Gonadotropin, pregnant mare serum:**

||| Remarks : No data available

### **Serious eye damage/eye irritation**

Not classified based on available information.

#### **Components:**

##### **Gonadotropin, pregnant mare serum:**

||| Remarks : No data available

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

#### **Components:**

##### **Gonadotropin, pregnant mare serum:**

||| Remarks : No data available

### **Chronic toxicity**

#### **Germ cell mutagenicity**

Not classified based on available information.

#### **Components:**

##### **Gonadotropin, pregnant mare serum:**

||| Genotoxicity in vivo : Test Type: Cytogenetic assay  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: positive  
Remarks: Not classified due to data which are conclusive although insufficient for classification.

### **Carcinogenicity**

Not classified based on available information.

#### **Components:**

##### **Gonadotropin, pregnant mare serum:**

||| Carcinogenicity - Assess- : No data available

**Serum Gonadotrophin Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
5445456-00010Date of last issue: 04.12.2024  
Date of first issue: 20.02.2020**[[ment****Reproductive toxicity**

May damage fertility. Suspected of damaging the unborn child.

**Components:****Gonadotropin, pregnant mare serum:**

Effects on fertility	: Test Type: Fertility Species: Rat Application Route: Subcutaneous Fertility: LOAEL: 10 µg/kg Result: Effects on fertility Remarks: May cause adverse reproductive effects. Based on data from similar materials
Effects on foetal development	: Remarks: May cause birth defects. Based on data from similar materials
Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments., Clear evidence of adverse effects on sexual function and fertility, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Gonadotropin, pregnant mare serum:**

Species	: Rat
NOAEL	: 1.5 mg/kg
Application Route	: Oral
Exposure time	: 3 Days
Symptoms	: No adverse effects

  

Species	: Rat
LOAEL	: 10 mg/kg
Application Route	: Oral
Exposure time	: 14 Days
Target Organs	: Reproductive organs

**Aspiration toxicity**

Not classified based on available information.

# SAFETY DATA SHEET



## Serum Gonadotrophin Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5445456-00010      Date of last issue: 04.12.2024  
Date of first issue: 20.02.2020

---

### Experience with human exposure

#### Components:

##### **Gonadotropin, pregnant mare serum:**

Inhalation	:	Symptoms: Headache, Fatigue, mood swings, altered mental status, Oedema, Allergic reactions, Effects on fertility
Skin contact	:	Remarks: May produce an allergic reaction.
Ingestion	:	Remarks: May be harmful if swallowed.

---

### Section 12: Ecological information

#### **Ecotoxicity**

No data available

#### **Persistence and degradability**

No data available

#### **Bioaccumulative potential**

No data available

#### **Mobility in soil**

No data available

#### **Other adverse effects**

No data available

---

### Section 13: Disposal considerations

#### **Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

### Section 14: Transport information

#### **International Regulations**

##### **UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

##### **IATA-DGR**

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable

# SAFETY DATA SHEET



## Serum Gonadotrophin Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5445456-00010      Date of last issue: 04.12.2024  
Date of first issue: 20.02.2020

---

Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Packing instruction (cargo aircraft) : Not applicable  
Packing instruction (passenger aircraft) : Not applicable

### IMDG-Code

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
EmS Code : Not applicable  
Marine pollutant : Not applicable

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### National Regulations

#### NZS 5433

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Hazchem Code : Not applicable

### Special precautions for user

Not applicable

---

### Section 15: Regulatory information

#### Safety, health and environmental regulations/legislation specific for the substance or mixture

##### HSNO Approval Number

HSR100759 Veterinary Medicines Non dispersive Open System Application Group Standard

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

##### HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

# SAFETY DATA SHEET



## Serum Gonadotrophin Formulation

Version 5.0	Revision Date: 14.04.2025	SDS Number: 5445456-00010	Date of last issue: 04.12.2024 Date of first issue: 20.02.2020
----------------	------------------------------	------------------------------	---

### The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

### Section 16: Other information

Revision Date : 14.04.2025

#### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recom-

# SAFETY DATA SHEET



## Serum Gonadotrophin Formulation

---

Version 5.0	Revision Date: 14.04.2025	SDS Number: 5445456-00010	Date of last issue: 04.12.2024 Date of first issue: 20.02.2020
----------------	------------------------------	------------------------------	---

---

Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN